A privately held biotechnology company, PolyPid Ltd. has developed unparalleled technology to improve drug performance via a patented delivery platform. The PolyPid platform offers a constant controlled release rate over a prolonged period via an impenetrable “dry reservoir”.
The PolyPid technology platform can be tailored to work with almost any Active Pharmaceutical Ingredient (API) including small molecules, peptides, proteins and nucleic acid-based drugs. The formulations can be pre-programmed to last for months, achieving both a desired release rate and optimal duration.
Due to its flexibility, this novel platform can address solutions for numerous medical needs in many therapeutic areas, including orthopedics, dental, oncology, urology, cardiology and infectious diseases. The PolyPid technology can also be used for coating surgically implanted medical devices.
PolyPid’s initial offering is the BonyPid™ family of products. BonyPid™ provides a local drug delivery platform, based on the PolyPid technology, and is designed to treat bone morbidities (orthopedic and dental).
The first BonyPid™ family product is fully biodegradable synthetic bone filler. This bone void filler consists of β-TCP particles, micro-coated with PolyPid controlled release formulation, and antibiotics. Via the local delivery platform, BonyPid™ treats and prevents bone contamination or infection caused during bone recovery by integrating bone filler with antibiotics.
The first-in-man clinical study using BonyPid™ is near completion of the follow-up stage. A European phase II clinical trial has also been initiated. Preliminary clinical data have clearly demonstrated BonyPid's safety and efficacy in early bone formation and anti-infective effects.